Patients with EGFR-mutant, oligometastatic NSCLC who received radiotherapy plus icotinib had longer overall and progression-free survival than those who received icotinib alone.
Half of patients surveyed said they would be less likely to open a patient portal account if they thought their parents would be able to access their medical information.